UNSPSC 51384628: Mofebutazone sodium

This classification denotes a nonsteroidal antiinflammatory drug C13H15N2O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73X92I1U1W, chemically known as 3,5-pyrazolidinedione, 4-butyl-1-phenyl-, sodium salt (1:1), but more generally known as mofebutazone sodium, which bears US NIH Compound Identifier 16639. European Medicines Agency schedules Mofebutazone sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03313MIG.

Most nations, for tariff and trade purposes, schedule mofebutazone sodium under HS 29331990 and SITC 51571. As of Q4 2014, MOFEBUTAZONE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CCCC[C-]1C(=O)[NH]N(C1=O)C2CCCCC2.[NA+].

UNSPSC 51384628 Mofebutazone sodium is a Commodity code that shows minimal alignment with recent state and local procurement activity. The single recent opportunity posted under this code — Seminole County, Florida's IFB 60459723LAS — solicits naloxone and safe drug deactivation systems, which fall outside the pharmaceutical anti-inflammatory scope that mofebutazone sodium denotes. The mismatch suggests either a tagging error in the county's procurement system or a misclassification of the opportunity at submission. State and local buyers have not posted solicitations for mofebutazone sodium specifically in the recent-opportunities dataset; the code shows little active purchasing momentum for this commodity line among state departments, counties, cities, school districts, or transit authorities.

Geographic activity cannot be meaningfully characterized beyond the single Florida posting, which does not represent an active market for the underlying commodity. The Seminole County opportunity itself — a naloxone and drug deactivation system procurement with quarterly deliveries, a two-year initial term with one-year renewal option, and response deadline of July 26, 2023 — reflects demand for harm-reduction products rather than veterinary or equine pharmaceuticals. Pursuit of this code should be deferred pending evidence of actual state and local solicitation for mofebutazone sodium or reclassification of mislabeled opportunities.